Biomea Fusion, Inc.

Biomea Fusion, Inc. reported a reduced net loss for the second quarter of 2026, with net loss decreasing to $8.3 million from $20.7 million in the prior year. Despite this improvement, the company's accumulated deficit reached $469.8 million, and its cash, cash equivalents, and restricted cash stood at $35.2 million as of June 30, 2026. Management expressed substantial doubt about the company's ability to continue as a going concern, indicating that current financial resources are insufficient to fund operations for the next twelve months and additional capital will be required.

Biomea Fusion, Inc. reported a net loss of $8.3 million for the second quarter ended June 30, 2026, a significant reduction from $20.7 million in the same period last year, with R&D expenses also decreasing. The company provided updates on its clinical programs, including ongoing Phase II trials for icovamenib in Type 2 diabetes with data expected in Q1 and Q2 2027. Initial 28-day weight reduction data from the Phase I GLP-131 (BMF-650) obesity trial is anticipated in Q3 2026, and a new Phase II collaboration for icovamenib in obesity was announced. The company projects its cash runway into Q2 2027.

Biomea Fusion presented new clinical and translational data for its investigational oral menin inhibitor, icovamenib, at the American Diabetes Association 86th Scientific Sessions. The data highlighted icovamenib's potential to improve endogenous insulin secretion and glycemic control in both Type 1 and Type 2 diabetes, with translational data supporting muscle preservation and fat reduction. Additionally, the company expanded its Phase I study for BMF-650, an oral GLP-1 receptor agonist, to optimize dose selection and evaluate a rapid one-step titration for enhanced weight loss potential.

Biomea Fusion reported a net loss of $12.4 million for Q1 2026, a significant improvement from $29.3 million in Q1 2025. However, the company's management expressed substantial doubt about its ability to continue as a going concern, citing insufficient financial resources for the next twelve months. Cash and cash equivalents decreased to $44.7 million from $55.8 million at year-end 2025.

Biomea Fusion reported a net loss of $12.4 million for the first quarter ended March 31, 2026, a significant improvement from $29.3 million in the same period of 2025. The company also provided positive updates on its clinical programs, including the successful completion of chronic toxicology studies for icovamenib and the initiation of Phase II trials for icovamenib in type 2 diabetes. Initial 28-day weight reduction data for BMF-650 in obesity is anticipated in Q2 2026, and the company projects its cash runway into Q1 2027.

Biomea Fusion successfully completed chronic toxicology studies for icovamenib, supporting its advancement to chronic clinical dosing. The company reported topline 52-week data from the Phase II COVALENT-112 trial in T1D, showing a 52% increase in C-peptide AUC at Week 12, and initiated two Phase II trials for icovamenib in T2D. The Phase I GLP-131 obesity trial is on track for initial 28-day weight reduction data in Q2 2026. For Q1 2026, Biomea reported a net loss of $12.4 million, a significant reduction from $29.3 million in Q1 2025, with R&D and G&A expenses also decreasing. The company projects a cash runway into Q1 2027.

Biomea Fusion announced that three abstracts for its investigational oral menin inhibitor, icovamenib, have been selected for late-breaking poster presentations at the American Diabetes Association (ADA) 86th Scientific Sessions in June 2026. The presentations will include data from both Type 1 and Type 2 diabetes studies, highlighting icovamenib's potential to improve beta cell function, support metabolic health, and improve endogenous insulin secretion. This marks a significant step in the clinical development of the Phase 2 drug.

Biomea Fusion, Inc. announced positive 52-week results from its Phase 2 COVALENT-112 trial for icovamenib in Type 1 Diabetes (T1D). Patients diagnosed within 0-3 years receiving 200 mg icovamenib showed a 52% increase in mean C-peptide AUC at Week 12, with effects largely preserved through Week 52. The drug was well-tolerated, and the company plans a new Phase 2 trial in collaboration with academic centers, starting in H2 2026, to evaluate extended dosing and combination therapy. A comprehensive dataset will be presented at the ADA Scientific Sessions in June.

Biomea Fusion, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026. Stockholders will vote on the election of two Class II directors, Rainer (Ramses) Erdtmann and Eric Aguiar, M.D., to serve until the 2029 annual meeting. Additionally, the agenda includes the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.